The DOI matches its Crossref record, with a small difference in title or year; 29 of the 29 references it cites were found in a registry or an index.
Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials*
Abstract
OBJECTIVE: Venous thromboembolism prevention during critical illness is a widely used quality metric. The objective of this systematic review was to systematically review the efficacy and safety of heparin thromboprophylaxis in medical-surgical patients in the ICU. DATA SOURCES: We searched EMBASE, MEDLINE, the Cochrane Controlled Trials Register, Clinicaltrials.gov, and personal files through May 2012. STUDY SELECTION: Randomized trials in adult medical-surgical ICU patients comparing any heparin (unfractionated heparin or low-molecular-weight heparin) with each other or no anticoagulant prophylaxis, evaluating deep vein thrombosis, pulmonary embolism, major bleeding, or mortality. DATA EXTRACTION: Independently, in duplicate, we abstracted trial characteristics, outcomes, and risk of bias. DATA SYNTHESIS: Seven trials involved 7,226 patients. Any heparin thromboprophylaxis compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0.41, 0.63]; p<0.0001; I=77%) and pulmonary embolism (risk ratio, 0.52 [95% CI, 0.28, 0.97]; p=0.04; I=0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.25]; p=0.43). Major bleeding (risk ratio, 0.82 [95% CI, 0.56, 1.21]; p=0.32; I=50%) and mortality (risk ratio, 0.89 [95% CI, 0.78, 1.02]; p=0.09; I=0%) rates were similar. Compared with unfractionated heparin, low-molecular-weight heparin reduced rates of pulmonary embolism (risk ratio, 0.62 [95% CI, 0.39, 1.00]; p=0.05; I=53%) and symptomatic pulmonary embolism (risk ratio, 0.58 [95% CI, 0.34, 0.97]; p=0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.08]; p=0.26; I=0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.25]; p=0.44; I=0%), major bleeding (risk ratio, 0.97 [95% CI, 0.75, 1.26]; p=0.83; I=0%), or mortality (risk ratio, 0.93 [95% CI, 0.82, 1.04]; p=0.20; I=31%). CONCLUSIONS: Trial evidence to date suggests that any type of heparin thromboprophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-surgical critically ill patients, and low-molecular-weight heparin compared with bid unfractionated heparin decreases pulmonary embolism and symptomatic pulmonary embolism. Major bleeding and mortality rates do not appear to be significantly influenced by heparin thromboprophylaxis in the ICU setting. Trial methodology, indirectness, and the heterogeneity and imprecision of some results temper inferences from this literature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The incidence of DVT acquired in the ICU may be as high as 10% [497], the incidence of acquired PE may be 2–4% [498, 499].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [498]
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Mismetti, P., Laporte, S., Darmon, J.-Y., Buchmüller, A., & Decousus, H. (2001) · Journal of British Surgery · doi:10.1046/j.0007-1323.2001.01800.x · Cited by 649
Deep Vein Thrombosis and Its Prevention in Critically Ill Adults
Attia, J., Ray, J. G., Cook, D. J., Douketis, J., Ginsberg, J. S., & Geerts, W. H. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.10.1268 · Cited by 617
Self-citationInterstitial Lung Disease: A Quantitative Study Using the Adaptive Multiple Feature Method
UPPALURI, R., HOFFMAN, E. A., SONKA, M., HUNNINGHAKE, G. W., & McLENNAN, G. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.2.9707145 · Cited by 564
Dentali, F., Douketis, J. D., Gianni, M., Lim, W., & Crowther, M. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-4-200702200-00007 · Cited by 544
Self-citationDalteparin versus Unfractionated Heparin in Critically Ill Patients
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014475 · Cited by 459
Pogue, J. M., & Yusuf, S. (1997) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00051-2 · Cited by 415
Prevalence of Deep Venous Thrombosis Among Patients in Medical Intensive Care
Hirsch, D. R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530040063042 · Cited by 318
Research works printed but not linked: 2
- Moser, 1981, JAMA, 246, 1422, 10.1001/jama.1981.03320130028018 · doi:10.1001/jama.1981.03320130028018
- Goldhaber, 2000, J Am Coll Cardiol, 35, 325A
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
“incidence of acquired PE may be 2%–4% (513, 514).”
BackgroundSelf-citationSurviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationRossaint, R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1265-x · Cited by 1,484
Metadata
- Authors
- Alhazzani, W., Lim, W., Jaeschke, R. Z., Murad, M. H., Cade, J., & Cook, D. J.
- Affiliations
- McMaster University (CA)
- Mayo Clinic (US)
- The Royal Melbourne Hospital (AU)
- Venue
- Critical Care Medicine
- Published
- 2013-09
- Volume
- 41
- Issue
- 9
- Pages
- 2088-2098
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2321905524
- Semantic Scholar
- f75126a5fd7772a2752c0acc656c0010d7a06dc7
- Cited by
- 168
- References
- 29
- Citations by year
- 2026: 9 · 2025: 3 · 2024: 10 · 2023: 11 · 2022: 19 · 2021: 15 · 2020: 23 · 2019: 19 · 2018: 8 · 2017: 9 · 2016: 10 · 2015: 13 · 2014: 16 · 2013: 3
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Keywords
- thromboprophylaxis, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, unfractionated heparin, major bleeding, mortality, intensive care unit patients, symptomatic pulmonary embolism, quality metrics, risk of bias
- MeSH terms
- Anticoagulants, Heparin, Low-Molecular-Weight, Hospitalization, Humans, Intensive Care Units, Randomized Controlled Trials as Topic, Critical Illness, Treatment Outcome, Venous Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials*. https://app.cochat.ai/papers/10.1097/ccm.0b013e31828cf104
- The paper
- Alhazzani, W., Lim, W., Jaeschke, R. Z., Murad, M. H., Cade, J., & Cook, D. J. (2013). Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials*. Critical Care Medicine. https://doi.org/10.1097/ccm.0b013e31828cf104
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.